US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...

Priyanka Chopra revealed her grandmother's secret to youthful skin: coconut oil. This natural ingredient combats microbes and reduces infla...

A 31-year-old man's psoriasis severely worsened after COVID-19, leading to significant weight loss and emotional distress. He found relief ...

Sun Pharmaceutical Industries has launched its innovative drug Ilumya in India. This medication treats moderate-to-severe plaque psoriasis....

Sun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This nov...

Dandruff causes temporary hair fall due to scalp inflammation, not permanent root damage, according to Dr. Gaurang Krishna. Genetic factors...

Psoriatic arthritis affects skin and joints with inflammation. This autoimmune condition causes pain, stiffness, and swelling. Early detect...

Eli Lilly has launched a new drug to treat moderate-to-severe plaque psoriasis in India. The drug, Copellor, is designed to specifically ta...

The permission to market the drug was granted for the treatment of cytokine release syndrome in 'moderate' to 'severe' Acute Respiratory Di...

Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA...

One of the most common skin conditions, psoriasis causes skin cells to build up, and form shiny scales and itchy, dry red patches.

In return, the Indian company will receive an initial upfront payment of $50 million and be eligible for development and regulatory milesto...

According to a filing with US SEC, the drug maker said as of March 31, 2014, it had 20 active products in the proprietary products pipeline.

Called ALZUMAb, it took 10 years in the making and "is recognition of innovation done by research and development wing of Biocon," said Kir...

Biotechnology major Biocon today said it is looking for partners to develop and market its novel biologic drug Itolizumab

The company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.

The product would be manufactured and formulated as an infusion drug at Biocon's biopharma manufacturing facility at Biocon Park, Bangalore.